skip to main content

Tirzepatide GIP GLP1 CKD — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

HardDiabetic Kidney DiseaseTirzepatide GIP GLP1 CKDESENeph

A 62-year-old man with CKD G4 and type 2 diabetes asks about Tirzepatide. His HbA1c is 70 mmol/mol despite Metformin, Dapagliflozin, and Semaglutide. What is Tirzepatide and does it have evidence in CKD?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Tirzepatide is a dual GIP/GLP-1 receptor agonist with potent glycaemic and weight-loss effects; kidney outcome data is emerging from the FLOW-like trials

Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It provides more potent glycaemic control and weight loss than GLP-1 RAs alone (SURPASS trials). While dedicated kidney outcome trials are ongoing, its cardiometabolic benefits suggest potential renal benefit. In CKD G4, dose adjustment may be needed depending on the specific agent. It represents the next evolution in incretin-based therapy beyond single GLP-1 RAs.

Reference: SURPASS Trials; KDIGO 2024 – CKD (GLP-1 RA section)